Publications by authors named "E Roesch"
This case report presents a comprehensive evaluation of the complex balance of therapeutic benefits and potential risks associated with the cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (ETI) therapy in managing an eight-year-old male with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI). While ETI therapy significantly enhanced exocrine pancreatic function, it led to hepatotoxicity, necessitating therapy discontinuation. Attempts to restart ETI at reduced doses were unsuccessful due to persistent hepatic dysfunction.
View Article and Find Full Text PDFBackground: This study aimed to determine if the neoadjuvant (NAT) KEYNOTE-522 regimen was associated with higher rates of pathologic complete response (pCR), corresponding to higher rates of breast conservation therapy (BCT) in early-stage triple-negative breast cancer (TNBC) patients.
Patients And Methods: Stage II-III TNBC patients diagnosed between 2019 and 2022 who underwent NAT were analyzed retrospectively. NAT with KEYNOTE-522 versus control NAT were compared for rates of BCT, axillary node dissection (ALND), pCR, and survival outcomes.
Article Synopsis
- Breast cancer during pregnancy, known as pregnancy-associated breast cancer (PABC), is uncommon but is one of the most frequent cancers found in pregnant women.
- PABC involves unique risk factors and treatment considerations, requiring a tailored management approach that prioritizes the health of both the mother and fetus.
- A comprehensive strategy that includes multidisciplinary collaboration and careful timing of treatments is essential, with post-delivery support addressing contraception, breastfeeding, and fertility issues also being crucial.
Introduction: The availability of cystic fibrosis transmembrane conductance regulator (CFTR) modulators opens the possibility of discontinuing some chronic pulmonary therapies to decrease cystic fibrosis (CF) treatment burden. However, CFTR modulators may not adequately address neutrophilic inflammation, which contributes to a self-perpetual cycle of viscous CF sputum, airway obstruction, inflammation, and lung function decline.
Areas Covered: This review discusses the emerging role of neutrophil extracellular traps in CF and its role in CF sputum viscosity, airway obstruction, and inflammation, based on a literature search of PubMed (1990-present).
Article Synopsis
- Metastatic breast cancer (mBC) is currently incurable, leading to inevitable disease progression in most patients during treatment.
- Endocrine therapy is the primary treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative mBC, but advancements in targeted therapies are improving patient outcomes.
- Effective treatment strategies require careful sequencing of therapies, emphasizing the importance of shared decision-making between patients and physicians, informed by genomic data and past treatments.